New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
11:58 EDTILMN, TMONew China rule prompts BGI to suspend trisomy testing, GenomeWeb says
BGI said a recent announcement from Chinese officials that genetic tests should be regulated has prompted the company to work with its collaborators to suspend the clinical application of its non-invasive fetal trisomy test in mainland China, according to GenomeWeb. Other providers of sequencing-based trisomy testing products, including Illumina (ILMN) and Thermo Fisher-owned (TMO) Life Technologies, declined to comment on the regulation notice, the report stated. The Fly notes that Illumina announced in January of 2010 that BGI had purchased 128 HiSeq 2000 sequencing systems. Illumina said at that time that revenue related to the sale of those instruments was expected to be recognized over the next three years. Reference Link
News For ILMN;TMO From The Last 14 Days
Check below for free stories on ILMN;TMO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 24, 2014
07:18 EDTILMNIllumina price target raised to $195 from $180 at Leerink
Leerink raised its price target for Illumina shares to $195 citing continued instrument momentum following the company's Q2 results. The firm keeps an Outperform rating on the stock.
July 23, 2014
16:23 EDTILMNIllumina raises FY14 EPS view to $2.26-$2.28 from $2.10-$2.15, consensus $2.17
Subscribe for More Information
16:19 EDTILMNIllumina reports Q2 EPS 57c, consensus 51c
Subscribe for More Information
15:30 EDTILMNNotable companies reporting after market close
Subscribe for More Information
13:39 EDTTMOThermo Fisher Q2 results bode well for PerkinElmer, Bruker, says Mizuho
Subscribe for More Information
06:21 EDTTMOThermo Fisher reports Q2 Life Sciences Solutions revenue $1.1B
Subscribe for More Information
06:20 EDTTMOThermo Fisher: Life Technologies integration 'going well'
The company adds that it is "on track to deliver a strong 2014."
06:02 EDTTMOThermo Fisher raises FY14 adjusted EPS to $6.85-$6.97 from $6.80-$6.95
Subscribe for More Information
06:00 EDTTMOThermo Fisher reports Q2 adjusted EPS $1.72, consensus $1.62
Subscribe for More Information
July 22, 2014
15:30 EDTTMONotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include PepsiCo (PEP) , consensus $1.23; Boeing (BA), consensus $2.01; Dow Chemical (DOW), consensus 72c; EMC (EMC), consensus 43c; Simon Property Group (SPG), consensus $2.13; Thermo Fisher (TMO), consensus $1.62; General Dynamics (GD), consensus $1.77; Freeport-McMoRan (FCX), consensus 49c; Delta Air Lines (DAL), consensus $1.04; Northrop Grumman (NOC), consensus $2.22; Whirlpool (WHR), consensus $2.91; B/E Aerospace (BEAV), consensus $1.07; Ryder (R), consensus $1.40; Owens Corning (OC), consensus 46c.
July 21, 2014
06:32 EDTILMNIllumina's NGS selected by Berry Genomics
Subscribe for More Information
July 17, 2014
10:00 EDTILMN, TMOOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:02 EDTTMOThermo Fisher to sell Cole-Palmer to GTCR for $480M in cash
Thermo Fisher Scientific has signed a definitive agreement to sell its Cole-Parmer channel business to private equity firm GTCR, LLC for $480M in cash. Thermo Fisher anticipates closing the transaction in Q3, subject to customary closing conditions and applicable regulatory approvals. The company expects an immaterial impact to 2014 adjusted EPS and will update annual guidance in its Q2 earnings release on July 23.
06:21 EDTTMOThermo Fisher initiated with a Buy at Citigroup
Target $137.
06:20 EDTILMNIllumina initiated with a Buy at Citigroup
Subscribe for More Information
July 16, 2014
11:28 EDTTMOLeon Cooperman gives 12 stock picks at CNBC conference
Subscribe for More Information
06:31 EDTILMNIllumina acquires Myraqa
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use